BioSpace News Archive

PerkinElmer, Inc. today announced it will release its full third quarter 2022 financial results on November 8, 2022.

PDS Biotechnology Corporation today announced that an abstract reporting on preclinical studies of two the company’s oncology pipeline products targeting multiple types of cancer has been accepted for presentation at the American Association of Cancer Research ( AACR ) Special Conference.

Bracco Diagnostics Inc. announced that it will feature the recently approved Gadopiclenol Injection, a novel, highly stable macrocyclic gadolinium-based contrast agent, commercialized as VUEWAY™ injection by Bracco, among a robust line of imaging products, devices, and support solutions, at the 2022 Radiological Society of North America annual congress, held November 27 through December 1.

Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL) today announced that the first patient has been dosed in the Phase 2 portion of its registrational Phase 1/2 clinical trial evaluating GC007g for the treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL) being conducted in China.

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the expanded commercial availability of CNSide for patients with metastatic melanoma.

9 Meters Biopharma, Inc., a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced that it will be executing a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20.

Revance Therapeutics, Inc. today announced the appointment of David A. Hollander, M.D., M.B.A., as Chief Medical Officer to lead clinical development, data science, medical affairs, scientific innovation, pharmacovigilance and regulatory affairs.

POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the publication of promising new pre-clinical data from the Company’s next-generation radioligand therapy (RLT) program for prostate cancer, PNT2001.

Minerva Neurosciences, Inc. (Nasdaq: NERV) today announced that the company has received a refusal to file letter from the U.S. Food and Drug Administration (FDA) regarding the company’s New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in patients with schizophrenia.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) will report its financial results for the third quarter of 2022 on Thursday, October 27, 2022, following the close of the market.